🇺🇸 FDA
Pipeline program

LCAR-B38M CAR-T Cell

CR108494

Phase 2 mab terminated

Quick answer

LCAR-B38M CAR-T Cell for Multiple Myeloma is a Phase 2 program (mab) at Legend Biotech Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
Legend Biotech Corp
Indication
Multiple Myeloma
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials